Therapy of cervical cancer using 131I-labeled nanoparticles

Wei Li, Danyang Sun, Ning Li, Yiming Shen, Yiming Hu, Jian Tan
2018 Journal of International Medical Research  
Objective: To evaluate the effectiveness of two kinds of Arg-Gly-Asp (RGD)-targeted 131 I-containing nanoliposomes for the treatment of cervical cancer in vitro and in vivo. Methods: The nanoparticle liposomes designated RGD-131 I-tyrosine peptide chain (TPC)-L and 131 I-RGD-L were prepared. The emulsion solvent evaporation method was used to encapsulate the polypeptide into liposomes. The quantity of entrapped polypeptide was measured using UV spectrophotometry. The labeling rates,
more » ... l purities, and total radioactivities were measured using paper chromatography. Cytotoxicity was assessed using the MTS assay and flow cytometry. Therapeutic efficacy was monitored using a mouse xenograft model of cervical cancer. Results: The labeling efficiency, radiochemical purity, and specific radioactivity of RGD-131 I-TPC-L were greater than those of 131 I-RGD-L. The cytotoxicity test indicated that late apoptosis of cells treated with RGD-131 I-TPC-L and 131 I-RGD-L was higher than that of cells treated with Na 131 I. The therapeutic effect of RGD-131 I-TPC-L was better than that of 31 I-RGD-L in the mouse model. Conclusions: The specific activity of liposome-encapsulated RGD-131 I-TPC-L was higher than that of 131 I-RGD-L, which labeled liposomes directly. Moreover, the RGD-131 I-TPC-L liposomes were more effective for killing xenografted tumor cells.
doi:10.1177/0300060518761787 pmid:29658363 pmcid:PMC6023049 fatcat:z6ziajxr45bx5cjwizx42jtfei